Clinuvel Pharmaceuticals (CUV) AI Stock Analysis

• Market Cap: AU$502.51M
• Dividend Yield: 0.38%
• Average Volume (3M): 97.23K
• Price to Earnings (P/E): 15.4
• Beta (1Y): 0.48
• Revenue Growth: 7.76%
• EPS Growth: 1.55%
• Country: AU
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.21
• Shares Outstanding: 50,200,740
• 10 Day Avg. Volume: 118,433
• 30 Day Avg. Volume: 97,231
• PEG Ratio: 0.00
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 5.47
• P/FCF Ratio: 12.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$19.97
• Price Target Upside: 80.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.71
• Revenue Forecast (FY): AU$99.23M

• Rating: 72 Outperform
• Price Target: AU$11.00 ▼(-0.72% Downside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is supported primarily by strong financial performance (profitability, cash strength, and minimal leverage) and a generally positive earnings update (growth, cash build, and clinical progress). This is tempered by weak technical signals (below key moving averages with negative MACD) and only moderate valuation support.

Positive Factors

Balance sheet strength

A long-established debt-free position and a 22% increase in cash reserves provide durable financial flexibility. This supports ongoing R&D, commercial roll-out and dividend policy, reduces refinancing risk and buffers operational volatility over the next several quarters.

Consistent profitability and margins

Sustained high margins and consecutive profitable years indicate a robust, cash-generative business model. Consistent dividend payouts reflect predictable cash conversion and management focus on shareholder returns, underpinning long-term financial stability.

Commercial expansion and revenue momentum

Cross-border market access gains and a growing accredited site network in the U.S., plus improving reimbursement, translate to structurally larger addressable sales. Breaking $100M revenue and site rollout momentum support medium-term sustainable revenue growth.

Negative Factors

Product concentration risk

Dependence on a single marketed product concentrates commercial and regulatory risk: any adverse payer decisions, safety events or competitive entrants could materially affect revenues and cash generation. Diversification remains limited over the next several quarters.

Regulatory setback for label expansion

A failed adolescent expansion approval with the EMA constrains market growth and delays access to an adjacent patient cohort. Regulatory pushbacks can materially extend timelines and increase development and market-access costs, limiting near-term addressable market expansion.

Rising operating costs

A sustained increase in operating and personnel costs can compress margins and reduce free cash flow if revenue growth slows. If higher expense run-rate persists for expansion and R&D, it will require continued cash generation or allocation trade-offs over the coming reporting periods.

Clinuvel Pharmaceuticals Business Overview & Revenue Model

Company Description

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe skin disorders and other related conditions. The company operates primarily in the healthcare sector, with a strong emphasis on photoprotection and skin repair. Its flagship product, SCENESSE (afamelanotide), is designed to provide protection against the harmful effects of ultraviolet (UV) light and is particularly beneficial for individuals with erythropoietic protoporphyria (EPP), a rare genetic disease that causes extreme sensitivity to sunlight.

How the Company Makes Money

Clinuvel Pharmaceuticals generates revenue primarily through the sale of its flagship product, SCENESSE, which is marketed in several countries for the treatment of EPP. The company has established a pricing strategy based on the unique value proposition of its product, given the specialized needs of its target patient population. Additional revenue streams may come from ongoing clinical trials and research partnerships aimed at expanding the applications of its core technology. Strategic collaborations with healthcare providers and institutions also play a significant role in enhancing the company's market presence and driving sales. Furthermore, Clinuvel may benefit from government reimbursements and support for rare disease treatments, which can significantly contribute to its overall earnings.

Clinuvel Pharmaceuticals Financial Statement Overview

Summary

Strong overall fundamentals: high profitability and margins, a very strong balance sheet with minimal leverage, and generally healthy cash generation. The main risk is slowing revenue growth and some variability in free cash flow.

Income Statement

Clinuvel Pharmaceuticals demonstrates strong profitability with a consistent increase in revenue over the years. The gross profit margin is high, indicating effective cost management, while the net profit margin remains robust, showcasing efficient operations. The EBIT and EBITDA margins are healthy, reflecting strong operational performance. However, the revenue growth rate has slowed recently, which could be a concern for future growth.

Balance Sheet

The balance sheet is strong with a very low debt-to-equity ratio, indicating minimal leverage and financial risk. The return on equity is impressive, reflecting effective use of shareholder funds to generate profits. The equity ratio is solid, suggesting a stable financial position with a significant portion of assets financed by equity.

Cash Flow

Clinuvel Pharmaceuticals shows a strong cash flow position with significant free cash flow growth, indicating efficient cash generation. The operating cash flow to net income ratio is favorable, suggesting good cash conversion from profits. However, the free cash flow to net income ratio, while strong, has shown some fluctuations, which could indicate variability in cash flow management.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	96.30M	95.02M	88.18M	78.32M	65.72M	47.98M
Gross Profit	61.36M	79.14M	80.45M	50.59M	46.62M	35.20M
EBITDA	41.65M	57.20M	56.28M	46.37M	35.08M	28.19M
Net Income	32.54M	36.17M	35.64M	30.60M	20.88M	24.73M
Balance Sheet
Total Assets	269.70M	271.75M	231.12M	194.52M	144.81M	108.57M
Cash, Cash Equivalents and Short-Term Investments	233.00M	224.11M	183.87M	156.81M	121.51M	82.69M
Total Debt	341.09K	528.53K	879.78K	999.87K	1.26M	1.30M
Total Liabilities	20.68M	30.94M	28.11M	29.89M	19.25M	9.83M
Stockholders Equity	249.02M	240.81M	203.01M	164.63M	125.56M	98.74M
Cash Flow
Free Cash Flow	40.08M	40.80M	31.48M	35.88M	39.44M	18.41M
Operating Cash Flow	40.47M	41.10M	37.05M	36.91M	39.87M	19.26M
Investing Cash Flow	-18.64M	-47.72M	-29.03M	-1.03M	-434.44K	-854.33K
Financing Cash Flow	-2.71M	-2.94M	-3.57M	-2.24M	-1.50M	-1.48M

Clinuvel Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CUV, the sentiment is Negative. The current price of 11.08 is below the 20-day moving average (MA) of 11.23, below the 50-day MA of 11.95, and below the 200-day MA of 11.47, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 36.15 is Neutral, neither overbought nor oversold. The STOCH value of 20.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CUV.

Clinuvel Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CUV	72 Outperform	AU$502.51M	15.41	15.90%	0.38%	7.76%	1.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PYC	51 Neutral	AU$1.42B	-18.15	-40.23%	―	―	-5.70%
IMM	49 Neutral	AU$567.38M	-6.72	-35.86%	―	―	-19.21%
CU6	47 Neutral	AU$1.34B	-12.93	-54.37%	―	―	-29.93%
BOT	44 Neutral	AU$124.21M	-1.20	-90.93%	―	456.50%	-457.14%
OPT	42 Neutral	AU$738.77M	-2.95	―	―	-80.08%	59.91%

Clinuvel Pharmaceuticals Corporate Events

Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue

Clinuvel Pharmaceuticals reported a 4% rise in half-year revenues to A$36.9 million, driven by increased commercial and Special Access Scheme sales of its flagship drug SCENESSE for erythropoietic protoporphyria and higher interest income on larger cash reserves. Patient demand strengthened, particularly in Europe, while net tangible asset backing per share improved to A$4.93 and cash reserves climbed 4% to A$233 million, underscoring a solid balance sheet.

Despite record December half-year revenues, profit after tax fell 26% to A$10.4 million as operating expenses rose 22% to support business expansion, resulting in a 26% decline in earnings per share to A$0.21. The company maintained its capital-return stance with a fully franked final dividend of 5 cents per share already paid for the prior financial year, signaling continued shareholder focus even as it invests for growth and broader market penetration.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings

Clinuvel Pharmaceuticals has issued an update noting its ongoing clinical and financial activities ahead of institutional investor meetings hosted by Jefferies, while emphasizing the inherent uncertainty in its forward-looking statements. The company highlights a broad range of risks that could materially affect future performance, from development, commercialisation and manufacturing delays across its core product lines, to regulatory, reimbursement, competitive, supply chain, and macroeconomic challenges, underlining the potential operational and financial volatility facing investors and other stakeholders.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L

Clinuvel Pharmaceuticals has begun dosing in a new preclinical study of VLRX-L, its in-house developed controlled-release liquid injectable peptide platform designed to deliver melanocortin-based and other peptide drugs with reproducible release profiles. The VLRX-L platform is the first novel pharmaceutical technology to emerge from the company’s expanded VALLAURIX Research, Development & Innovation Centre in Singapore, where a multi-year, Singapore Economic Development Board-backed investment is building capabilities in injectable controlled-release formulations, signalling Clinuvel’s ambition to broaden its product pipeline and strengthen its position in peptide-based drug delivery over the coming years, with initial preclinical readouts expected in the second half of 2026.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients

Clinuvel Pharmaceuticals has reported new clinical data from four Fitzpatrick VI (darker skin type) adult patients enrolled in its ongoing CUV105 study evaluating SCENESSE® in vitiligo, presented at the Regional Dermatology Training Center conference in Tanzania. The patients, who completed a 140-day treatment regimen of seven SCENESSE® implants combined with up to 40 narrowband UVB sessions and were followed through day 224, tolerated the therapy well, expressed satisfaction with outcomes, and showed repigmentation patterns consistent with earlier cases, reinforcing the potential of the drug to restore pigmentation and identity in vitiligo patients and supporting Clinuvel’s decision to accelerate its clinical development program in this indication.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights

Clinuvel Pharmaceuticals Limited, an Australian listed biopharmaceutical company trading on the ASX under the code CUV, focuses on developing and commercialising pharmaceutical products. The company has announced the lapse of 5,425 performance rights (security code CUVAK) as of 31 December 2025, due to the relevant conditions not being met or becoming incapable of being satisfied, resulting in a small reduction in its pool of potential equity-based remuneration instruments and no change to existing ordinary shares on issue.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

Clinuvel Files U.S. GAAP 20-F as It Targets Nasdaq ADR Uplisting

Clinuvel Pharmaceuticals has filed a draft registration statement, including a U.S. GAAP-compliant Form 20-F annual report for the year to 30 June 2025, with the U.S. Securities and Exchange Commission as it moves to upgrade its American Depositary Receipt program from Level I to Level II and pursue a listing on the Nasdaq Stock Market. The step, aimed at better serving its sizeable U.S. investor base and expanding American operations, marks a significant escalation in the company’s engagement with U.S. capital markets, although the uplisting remains contingent on SEC review and Nasdaq listing approvals, and there is no assurance the process will be completed within the anticipated timeframe.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

CLINUVEL Expands Singapore RD&I Centre for Advanced Peptide Therapies

CLINUVEL PHARMACEUTICALS LTD has announced a significant expansion of its VALLAURIX Research, Development, and Innovation Centre in Singapore, supported by the Singapore Economic Development Board. This strategic five-year investment aims to transform the facility into a global hub for developing advanced peptide therapies, focusing on liquid controlled-release drug products. The expansion underscores CLINUVEL’s commitment to innovation in peptide-based medicine and strengthens its position in the biotech industry by leveraging Singapore’s vibrant ecosystem. This move is expected to enhance the company’s capabilities in delivering next-generation therapeutic solutions and optimize therapeutic dosing for patients, positioning CLINUVEL at the forefront of peptide delivery technologies.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

CLINUVEL Targets Mid-2026 for European Filing of NEURACTHEL® Instant

CLINUVEL Pharmaceuticals announced a significant milestone with the planned mid-2026 European regulatory filing for NEURACTHEL® Instant, a generic adrenocorticotropic hormone (ACTH) formulation. This follows the successful validation of the manufacturing process, ensuring a reliable supply chain and de-risking the commercial pathway. The strategic filing aims to accelerate market entry in key European markets with known demand, enhancing CLINUVEL’s portfolio of melanocortin-based therapies. The company is also investing in infrastructure to support future pharmaceutical products, aiming to broaden the clinical applications of ACTH and other melanocortins.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.